MannKind at Oppenheimer: 2025 Revenue Jumps 46%, Eyes $450M+ in 2026 on Afrezza and FUROSCIX [Yahoo! Finance]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: Yahoo! Finance
revenue could top $450 million , citing Afrezza pediatric expansion, a potential FUROSCIX auto-injector and Tyvaso DPI royalties as key drivers. The inhaled nintedanib program MNKD-201 has entered Phase 1 (two cohorts in IPF patients) with four enrolled and the first 12-patient cohort expected to finish in ~30–45 days, and a Phase 2 planned for early Q2 that the company says is fully funded. Afrezza's pediatric PDUFA date is May 29 ; the INHALE-1ST trial is rolling out initial sites, the company is exploring a 2-unit cartridge for finer titration, and management views low pediatric awareness as an opportunity for relaunch. Interested in MannKind Corporation? Here are five stocks we like better. MannKind (NASDAQ:MNKD) executives highlighted accelerating revenue growth, pipeline priorities, and commercialization plans during a discussion at Oppenheimer's 36th Annual Healthcare Life Sciences Conference, held following the company's fourth-quarter and full-year 2025 earnings relea
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- MannKind (MNKD) had its price target lowered by Wedbush from $10.00 to $8.00. They now have an "outperform" rating on the stock.MarketBeat
- MannKind to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- MannKind to Participate in Upcoming Investor ConferencesGlobeNewswire
- MannKind Corporation (MNKD) Outlines Expansion Plans and Revenue Targets [Yahoo! Finance]Yahoo! Finance
- MannKind (MNKD) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c)" to "sell (d+)".MarketBeat
MNKD
Earnings
- 2/26/26 - Beat
MNKD
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- MNKD's page on the SEC website